期刊
MOVEMENT DISORDERS
卷 34, 期 1, 页码 9-21出版社
WILEY
DOI: 10.1002/mds.27583
关键词
alpha-synuclein; GBA1; GCase; Lewy bodies; Parkinson's disease
资金
- Italian Ministry of Health (Ricerca Corrente)
- EU Joint Programme - Neurodegenerative Disease Research (JPND) project GBA-PARK
- Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy
- Leonard Wolfson Experimental Neurology Centre [PR/ylr/18575]
- Medical Research Council UK [MR/M006646/1]
- UCLH Biomedical Research Centre Grant from the National Institute for Health Research [NIHR] [RCF73TS201145980]
- NIHR
- Spanish Ministry of Health [BFU2017-82407-R]
- ERC [340527]
- CiberNed Intramural Project [2017/02]
- Department of Health, Government of Navarra -FEDER [046-2017]
- MRC [MR/N028651/1, MR/M006646/1] Funding Source: UKRI
Glucocerebrosidase is a lysosomal enzyme. The characterization of a direct link between mutations in the gene coding for glucocerebrosidase (GBA1) with the development of Parkinson's disease and dementia with Lewy bodies has heightened interest in this enzyme. Although the mechanisms through which glucocerebrosidase regulates the homeostasis of -synuclein remains poorly understood, the identification of reduced glucocerebrosidase activity in the brains of patients with PD and dementia with Lewy bodies has paved the way for the development of novel therapeutic strategies directed at enhancing glucocerebrosidase activity and reducing -synuclein burden, thereby slowing down or even preventing neuronal death. Here we reviewed the current literature relating to the mechanisms underlying the cross talk between glucocerebrosidase and -synuclein, the GBA1 mutation-associated clinical phenotypes, and ongoing therapeutic approaches targeting glucocerebrosidase. (c) 2018 International Parkinson and Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据